Navigation Links
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Date:12/4/2007

t program evaluating the efficacy and safety of this novel biologic in the treatment of moderate to severe plaque psoriasis," said Jerome A. Boscia, M.D., senior vice president, Clinical R&D, Centocor, Inc. "We remain committed to developing safe and effective new therapies for patients with inflammatory diseases like psoriasis through continued research and development in disease areas where unmet needs in treatment remain."

About Psoriasis

Psoriasis is a chronic, immune-mediated disease, which results from the overproduction of skin cells resulting in their accumulation on the surface of the skin, which causes red, scaly plaques that may itch and bleed. It is estimated that approximately 7.5 million people in the United States and 10 million Europeans are living with psoriasis and nearly one-quarter of those people have cases that are considered moderate to severe.(1)

About Ustekinumab

Ustekinumab is a new, human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis, and is being investigated as an infrequently administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in regulating the immune system and that are also believed to play a role in immune-mediated inflammatory disorders.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies have exclusive marketing rights in all countries outside of the United States. Centocor, Inc. and the Janssen-Cilag companies are members of the Johnson & Johnson family of companies.

About Centocor, Inc.

Centocor is harnessing the power of world-leading research and biomanufacturing to deliver innovative biomedicines that transform patients' lives. Centocor has already brought innovation to the treatment of Crohn's dise
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CLIA Waiver Submitted for Rapid HIV Test Employs StatSures Barrel Technology
2. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
3. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
4. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
5. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
6. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
7. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 According to a new ... Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) - ... 2013-2019" the global endoscopy devices market was valued at ... grow at a CAGR of 6.8% from 2013 to ... billion in 2019. Browse the full Endoscopy ...
(Date:7/10/2014)... India , July 11, 2014  Major ... treatment of cancer are being highlighted in a ... Mumbai from 10-12 July, 2014.  Renowned national ... to share best practices and exchange knowledge on ... precise, accurate and efficient. The ...
(Date:7/10/2014)...  RESMED INC. (NYSE: RMD ) today announced ... ended June 30, 2014 results on Thursday, July 31, 2014, ... release with ResMed,s results will be issued after 1:00 p.m. ... to discuss operating results and future outlook. The ... Pacific Time and the live webcast of the call can ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Soligenix, Inc. (OTC Bulletin Board: SNGX ) ... today that it has appointed Kevin Horgan, MD, as ... Horgan is a board-certified gastroenterologist with a research background ... patients with inflammatory bowel disease, including graft-versus-host disease (GVHD). ...
... JOLLA, Calif., Feb. 1, 2011 Transdel Pharmaceuticals, ... a specialty pharmaceutical company focused on developing topically ... announced that the Company has been exploring strategic alternatives ... American MedTech Advisors and ESC Advisors, a division ...
Cached Medicine Technology:Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 2Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 3Soligenix Appoints Kevin Horgan, MD, as Chief Medical Officer 4Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 2Transdel Pharmaceuticals Announces Exploration of Strategic Alternatives 3
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... According to a new market research report “Internet ... (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, RFID), Application Vertical (Building ... & Geography - Global Trends & Forecasts to 2014 ... was worth $1029.5 Billion in 2013, and is expected ... CAGR of 4.08% from 2014 to 2020. , ...
(Date:7/11/2014)... The Miriam Hospital have found that people with ... rates of smoking than those without mobility impairments. ... to attempt quitting than those without mobility impairments, ... for this population. The study and its findings ... the American Journal of Public Health . ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 (HealthDay ... worldwide scourge of dengue fever was somewhat successful in a ... dengue fever in 56 percent of the 10,000 kids who ... than 88 percent of them from severe disease. In the ... death. "This vaccine has already proven to be safe," ...
(Date:7/11/2014)... 2014 Last month Watkins Insurance Group ... joins the agency as a specialist in insurance and ... a Bachelor’s Degree in Business Administration from Texas State ... will manage everything from performance and payment bonds, license ... specialized needs for those in the asphalt supplier industry. ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 3 The following is being issued by The American ... by federally funded organizations operating in every state has had ... during a period when hospital performance improved faster than outpatient ... The annual National Healthcare Quality Report, just released by the ...
... treatment or not, study finds , WEDNESDAY, June 3 ... before a mammogram doesn,t lower the likelihood of being ... than 1,700 women aged 45 to 80 has found. ... women,s breasts -- and make mammograms harder to read," ...
... PLYMOUTH MEETING, Pa., June 3 /PRNewswire-Asia-FirstCall/ -- ... or the "Company") today announced,that it will be featured ... conference call series to discuss the impact of,China Healthcare ... will be hosted by Ding Ding, Ph.D., SIG,s senior ...
... , -- Record non-infant formula nutritional sales of $9.8 million ... Earnings per share of $0.33, an increase of 20% over last ... million (Year-to-date operating cash flow of $26 million) , -- Full ... pre-tax earnings growth of 10% to 15% over fiscal 2008 ...
... IMAGINE Software, a leading provider of ... within the IMAGINEradiology(TM) practice management system at IMAGINE,s 2009 ... , , The system received a number ... deployment and maintenance distribution through application virtualization; "I-Connect," ...
... of Obama and His Agenda; Jon Stewart Bests Stephen Colbert, ... 3 Progressives gathered at this week,s "America,s Future Now" ... ,s first 100 days, but they are very focused on ... straw poll of participants conducted by Greenberg Quinlan Rosner Research ...
Cached Medicine News:Health News:QIO Support Accelerates Hospital Improvement in Heart Care, Researchers Find 2Health News:Pausing Hormone Therapy Doesn't Cut Mammogram Recalls 2Health News:BMP Sunstone to be Featured on SIG's 'China Healthcare On Call' Conference Call Series 2Health News:Martek Announces Second Quarter 2009 Financial Results 2Health News:Martek Announces Second Quarter 2009 Financial Results 3Health News:Martek Announces Second Quarter 2009 Financial Results 4Health News:Martek Announces Second Quarter 2009 Financial Results 5Health News:Martek Announces Second Quarter 2009 Financial Results 6Health News:Martek Announces Second Quarter 2009 Financial Results 7Health News:Martek Announces Second Quarter 2009 Financial Results 8Health News:Martek Announces Second Quarter 2009 Financial Results 9Health News:Martek Announces Second Quarter 2009 Financial Results 10Health News:Martek Announces Second Quarter 2009 Financial Results 11Health News:Martek Announces Second Quarter 2009 Financial Results 12Health News:IMAGINE Software Unveils Advanced IMAGINEradiology(TM) Features 2Health News:'America's Future Now' Straw Poll: Progressives See Health Care Reform With Public Option As Top Priority 2
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
... a minimally invasive treatment for prostate and ... to use, SeedNet provides optimum accuracy, efficiency ... SeedNet is the new generation in cryotherapy ... the SeedNet system, produce iceballs of extreme ...
Li Brand™ Surgical Hemostat. ("dissecting clamp") For NSV and other procedures....
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings...
Medicine Products: